Emerging pipeline of protein therapeutics
Results from early in vivo screening assays indicate activity on intestinal cell production in about half of the recombinant proteins and synthetic peptides tested. Epistem is advancing 4 protein therapeutic leads in oncology and GI diseases.
Checklist for preclinical biology
| Criteria | Description |
| Intellectual property | Novelty, prior art, composition of matter, 2nd generation drugs |
| Proteins | Production, purification, analytics |
| Activity assays | Determine specific activity and stability of proteins |
| In vivo activity | Demonstrate robust activity against benchmarks |
| Biological MOA - cellular response to protein regulator | |
| Dose/schedule optimisation | |
| Disease models | Industry-standard models to benchmark candidates |
| Biological relevance | Steady state, response to damage, involved in disease |
| Precedence | Human studies in related proteins |